重庆朝天门的江水里，长江与嘉陵江激荡而出的"夹马水"，带着一股不服输的闯劲；成都平原的晨光 中，岷江与沱江滋养而出的创新动能，不断转化为各赛道各企业的干劲。这片满是巴蜀烟火气的土地， 随着成渝地区双城经济圈建设的稳步推进，正展现出前所未有的发展活力。五年来，成渝地区双城经济 圈经济总量从6.3万亿元增长到8.7万亿元，对西部乃至全国高质量发展的支撑带动作用愈发明显。 在这幅波澜壮阔的发展画卷中，成渝上市公司犹如一颗颗璀璨的星辰，在各自赛道上精耕细作、创新突 破，构建了成渝产业矩阵的坚实骨架，成为双城经济圈建设最实在的"硬帮手"。 在成渝重点培育的生物医药赛道上，众多企业以创新为刃，开辟着行业发展新空间。 今年，是中自科技与催化剂打交道的第二十年。二十年间，公司将实验室的创新样品不断转化为市场的 成熟产品，摸索出一条独特的"催化之道"。同时，公司以创新为矛不断拓展业务布局，现已构建起"催 化剂+新能源+新材料"三位一体的业务矩阵。 再升科技则描绘了一幅"点石成金"的产业蓝图：依托对"一粒砂"的深度研发，公司在超细纤维材料方面 构筑了核心技术的"护城河"，并全力拓展技术应用空间，将产品和服务广泛应用于空气净化、保 ...

Group 1: Mona Lisa (002918) - The company's revenue from distribution channels decreased by 10% year-on-year in the first half of 2025, while the engineering channel saw a decline of 42.68% [1] - The distribution channel accounted for 82.98% of revenue in Q2, with ongoing declines in engineering [1] - The company is facing intense industry competition with no positive price changes, and is focusing on cost reduction and efficiency improvements [1] - The strategic customer business proportion has dropped to 17%, with 83% of demand coming from non-real estate sectors [1] - The company maintains a "large tiles, large building materials, large home" strategy, with low financial investment proportion [1] Group 2: Mountain Outside Mountain - The domestic market for blood purification equipment generated revenue of 152 million yuan, a year-on-year increase of 14.60% [2] - Blood purification consumables revenue reached 85.34 million yuan, up 46.17%, with self-produced consumables growing by 91.90% [2] - R&D investment increased by 37.12% to 36.51 million yuan, while sales expenses rose by 26.64% to 62.80 million yuan [2] - The overseas market revenue was 86.82 million yuan, reflecting a growth of 41.30%, with significant increases in North America and Africa [2] - The company is a drafting unit for national standards and is enhancing its international competitiveness through core technology [2] Group 3: Leyard (300296) - The smart display segment experienced a 20% quarter-on-quarter growth, driven by high demand in overseas markets, particularly North America [3] - Business growth is supported by demand from cinemas, virtual shooting, and large events [3] - The company is optimizing production capacity across its factories in Slovakia, Shenzhen, and Wuxi to mitigate tariff impacts [3] - The AR glasses are expected to launch in October, targeting B-end customers [3] - The AI and spatial computing segments saw a year-on-year decline due to price reductions and increased R&D investment [3]

Core Viewpoint - The report details the equity changes of Chongqing Shanwaishan Blood Purification Technology Co., Ltd. due to the share reduction by major shareholders, which does not trigger a change in control or a mandatory tender offer [19][20][22]. Group 1: Shareholder Information - The equity change involves three main parties: Hunan Xiangjiang Liyuan Investment Management Co., Ltd. - Hunan Xiangjiang Dajiankang Venture Capital Partnership (Limited Partnership), Hunan Xiangjiang Liyuan Investment Management Co., Ltd. - Hunan Xiangjiang Liyuan Jiankun Venture Capital Partnership (Limited Partnership), and the original shareholder You Xinnong [19][20]. - The total shares held by these parties decreased from 18,623,449 shares (12.87% of total shares) to 32,131,623 shares (10.00% of total shares) after the reduction [22]. Group 2: Share Reduction Details - The share reduction was executed through centralized bidding transactions, with You Xinnong reducing 1,937,703 shares from June 18, 2024, to September 15, 2024, and the other two parties reducing a total of 7,276,593 shares from June 6, 2025, to August 4, 2025 [8][20][22]. - The total share capital of the company increased from 144,730,259 shares at the time of listing to 321,315,646 shares after two rounds of capital reserve transfers [7][22]. Group 3: Future Plans - The parties involved have no current plans to increase or decrease their holdings beyond the disclosed reduction plan, which allows for a maximum reduction of 12,852,625 shares, representing up to 4.00% of the total share capital [5][20]. - The report confirms that the equity change does not affect the company's controlling shareholder or actual controller [9][19].

Group 1: Fund Performance - The fund "淳厚信睿C" has achieved a one-year return of 54.03%, outperforming the benchmark growth rate of 17.02% and the CSI Mixed Fund Index return of 18.18%, ranking in the top 5 among mixed funds as of July 21, 2025 [1] - Over the past two years, the fund's return is 46.27%, significantly higher than the performance benchmark of 12.24% and the CSI Mixed Fund Index return of 4.00% [1] - The fund's maximum drawdown over the past three years is 30.32%, which is better than the average level of similar mixed funds, with a maximum drawdown recovery time of 246 days, ranking in the top 20 among similar funds [1] Group 2: Fund Size and Shareholder Structure - As of June 30, 2025, the fund's total management scale reached 4.08 billion yuan, with a total of 173 million shares outstanding [1] - The institutional shareholder ratio of the fund is 53.67% according to the 2024 annual report [1] - The fund had 5 shareholders with a total holding size of 61.12 million yuan, accounting for 14.96% of the total holdings as of the mid-2025 report [1] Group 3: Industry Insights - The number of end-stage renal disease (ESRD) patients in China increased from 3.025 million in 2019 to 4.126 million in 2023, with a CAGR of 8.1%, significantly higher than the global growth rate of 5.1%, indicating a growing market for blood dialysis [3] - The percentage of ESRD patients receiving dialysis treatment in China is approximately 26%, which is lower than the global average of 37% and significantly below the average of 75% in developed countries, suggesting substantial market potential for blood dialysis [3] - The sales revenue of blood purification equipment for 山外山 company in Q1 2025 reached 127.49 million yuan, showing strong growth in both domestic and international markets [3] Group 4: Competitive Advantages - 山外山 company has a strong technological innovation advantage, with national-level research and development platforms, making it a leading domestic blood purification equipment manufacturer [3] - The company emphasizes product quality with a comprehensive quality management system, ensuring the safety, reliability, and stability of its products [3] - 山外山 company has established a robust after-sales service system, enabling quick responses to customer needs and providing efficient technical support [3] Group 5: Future Developments - The company plans to closely monitor the progress of medical equipment update projects, as the National Development and Reform Commission has announced policies to enhance funding efficiency and support equipment updates [3][4] - In Q1 2025, the medical services segment of 山外山 company achieved a revenue of 16.27 million yuan, a year-on-year increase of 43.52%, indicating growth in its blood dialysis service offerings [4] - The company has established six chain blood dialysis centers and is developing standards for their construction and operation, along with a talent training system [4]